A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Tesamorelin is a 44-amino-acid growth hormone-releasing hormone (GHRH) analog — the strongest and longest-acting compound in its class, producing a bigger, more sustained growth hormone response than Sermorelin. It’s also the only FDA-approved growth hormone secretagogue currently in clinical use, approved as EGRIFTA (2010) and, in an updated formulation, EGRIFTA WR (2025) — specifically for reducing excess abdominal (visceral) fat in patients with HIV-associated lipodystrophy.
Visceral fat isn’t just extra padding — it behaves like an active inflammatory organ, producing substances that drive insulin resistance and cardiovascular risk. Growth hormone preferentially targets this type of fat for breakdown, which is why Tesamorelin’s stronger GH stimulus produces a disproportionate reduction specifically in visceral fat compared to fat just under the skin. In its approved Phase 3 trials, it produced roughly a 19.6% reduction in visceral adipose tissue compared to placebo.
Worth being clear-eyed about: Tesamorelin’s visceral-fat-reducing effect isn’t unique to it specifically — any growth-hormone-axis peptide that raises GH will tend to reduce visceral fat, since that’s how growth hormone itself behaves in the body. What makes Tesamorelin different is that it’s the one compound in this category with FDA approval and the strongest clinical evidence behind it. Outside of its approved HIV-lipodystrophy indication, it’s sometimes used off-label as part of an individualized metabolic or body-composition protocol, with fasting glucose and IGF-1 monitored along the way since it produces a stronger GH stimulus than Sermorelin or CJC-1295.
Because Tesamorelin drives a stronger fat-burning (lipolytic) demand than gentler GH-axis peptides, the nutrient cofactors that support fat metabolism matter more here, not less. Our clinical reference specifically flags B1, B2, B5, and acetyl-L-carnitine as priority cofactors for the fat-oxidation pathway Tesamorelin activates, alongside the general GH-axis needs of zinc, magnesium, and adequate dietary protein.
Tesamorelin is FDA-approved under the brand name EGRIFTA (and the updated EGRIFTA WR formulation) specifically for HIV-associated lipodystrophy. Use for any other purpose, including general metabolic or longevity goals, is considered off-label. Active or suspected malignancy is an explicit contraindication on the FDA label, and because it produces a stronger GH stimulus than gentler options, fasting glucose and HbA1c monitoring is especially important. Visceral fat reduction typically returns toward baseline within 6–12 months of stopping, which is worth factoring into any long-term plan.
The tesamorelin research looked specifically at visceral (belly) fat, and it showed a marked reduction. That said, we believe the result came less from tesamorelin itself and more from the way growth hormone is designed to work in the body. Raising HGH always helps burn fat, so anything that raises HGH should physiologically help your body use fat as a fuel source.
Much of your fat processing happens in the liver, through lipolysis and lipoprotein lipase. Visceral fat responds more strongly to these signals than the fat under your skin, so those cells get hit harder and broken down faster. To be fair, this is a growth hormone process, not something unique to tesamorelin. Anything that raises HGH can help with it.
They all raise your own growth hormone instead of injecting HGH, but they are not equal. CJC-1295 (especially with DAC) and ipamorelin generally drive the biggest pulses, tesamorelin gives a solid daily GHRH pulse, and sermorelin gives the shortest, mildest one. The real difference: tesamorelin is the full-length GHRH analog with actual visceral-fat trial data, sermorelin is plain short GHRH, and CJC-1295/ipamorelin is a two-receptor stack (GHRH plus ghrelin) with more growth hormone output but almost no outcome data.
Anyone who wants to lose visceral fat and build muscle tissue. It also helps with insulin resistance.
It can. It shifts the body into fat-burning mode and can improve insulin resistance, which can lower fasting blood sugar. As for side effects, it’s common to feel flushed after an injection.
It depends on the person’s goals. Many people run it for 2 to 3 months, and several run it much longer. How long you use any peptide should be tied to your specific goals.
Learn more about the pathway Tesamorelin works within: Growth Hormone & IGF-1. Compare with Sermorelin and Ipamorelin, or see Hexarelin.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
